ATE248189T1 - Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung - Google Patents

Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung

Info

Publication number
ATE248189T1
ATE248189T1 AT98963419T AT98963419T ATE248189T1 AT E248189 T1 ATE248189 T1 AT E248189T1 AT 98963419 T AT98963419 T AT 98963419T AT 98963419 T AT98963419 T AT 98963419T AT E248189 T1 ATE248189 T1 AT E248189T1
Authority
AT
Austria
Prior art keywords
vasodilator
hybridoma cells
antibodies against
vasp
obtaining
Prior art date
Application number
AT98963419T
Other languages
English (en)
Inventor
Martin Eigenthaler
Heinz Hoschuetzky
Ulrich Walter
Original Assignee
Vasopharm Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19749091A external-priority patent/DE19749091C1/de
Application filed by Vasopharm Biotech Gmbh filed Critical Vasopharm Biotech Gmbh
Application granted granted Critical
Publication of ATE248189T1 publication Critical patent/ATE248189T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
AT98963419T 1997-11-07 1998-11-06 Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung ATE248189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19749091A DE19749091C1 (de) 1997-11-07 1997-11-07 Antikörper gegen phosphoryliertes VASP (Vasodilator-Stimuliertes Phosphoprotein), Hybridomzellen zu dessen Herstellung sowie dessen Anwendung
US7937598P 1998-03-26 1998-03-26
PCT/EP1998/007103 WO1999024473A1 (en) 1997-11-07 1998-11-06 Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use

Publications (1)

Publication Number Publication Date
ATE248189T1 true ATE248189T1 (de) 2003-09-15

Family

ID=26041380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963419T ATE248189T1 (de) 1997-11-07 1998-11-06 Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung

Country Status (16)

Country Link
US (2) US6649421B1 (de)
EP (1) EP1042368B1 (de)
JP (1) JP5031140B2 (de)
KR (1) KR100513418B1 (de)
CN (1) CN1188426C (de)
AT (1) ATE248189T1 (de)
AU (1) AU753557B2 (de)
BR (1) BR9813988A (de)
CA (1) CA2308604C (de)
CZ (1) CZ299889B6 (de)
ES (1) ES2205593T3 (de)
HU (1) HU222411B1 (de)
PL (1) PL195985B1 (de)
RU (1) RU2218178C2 (de)
TR (1) TR200001265T2 (de)
WO (1) WO1999024473A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10029210A1 (de) * 2000-06-14 2002-01-31 Vasopharm Biotech Gmbh & Co Kg Testsystem sowie dessen Verwendung
US6951947B2 (en) * 2000-07-13 2005-10-04 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
US7176037B2 (en) * 2000-07-13 2007-02-13 The Scripps Research Institute Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
EP1182263A1 (de) * 2000-08-11 2002-02-27 Evotec OAI AG Verfahren zum Nachweis einer Threonin- oder Serinkinasenaktivität
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
WO2002050121A1 (fr) * 2000-12-13 2002-06-27 Taisho Pharmaceutical Co.,Ltd. Nouvel anticorps
JP2007529718A (ja) * 2004-03-12 2007-10-25 ザ スクリップス リサーチ インスティチュート 蛋白質活性の検出および定量のための蛍光シグナル発光型生細胞バイオセンサー分子ならびに色素
CN103102411A (zh) * 2009-06-11 2013-05-15 北京华大蛋白质研发中心有限公司 一种制备针对糖基化修饰蛋白质的单克隆抗体杂交瘤的方法
FR2946756A1 (fr) * 2009-06-12 2010-12-17 Biocytex Dosage en sang total d'un biomarqueur intracellulaire appartenant a une voie de signalisation cellulaire- utilisation pour mesurer l'activation d'une population cellulaire determinee
EP3509613A4 (de) * 2016-09-07 2020-12-02 Vanderbilt University Vasoaktive polypeptide zur entspannung der glatten muskulatur
CN112730826A (zh) * 2020-12-23 2021-04-30 中南大学湘雅三医院 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用
CN113238062B (zh) * 2021-07-13 2021-09-28 湖南菲思特精准医疗科技有限公司 一种用于人磷酸化血管扩张刺激磷蛋白光激化学发光均相免疫检测试剂盒及其检测方法
CN114002440B (zh) * 2021-12-30 2022-04-01 湖南菲思特精准医疗科技有限公司 一种用于人磷酸化血管扩张刺激蛋白的酶联免疫检测试剂盒及其检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4281393A (en) 1992-04-10 1993-11-18 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection

Also Published As

Publication number Publication date
EP1042368B1 (de) 2003-08-27
CZ299889B6 (cs) 2008-12-29
KR20010031830A (ko) 2001-04-16
AU753557B2 (en) 2002-10-24
ES2205593T3 (es) 2004-05-01
HU222411B1 (hu) 2003-06-28
PL340465A1 (en) 2001-02-12
CN1188426C (zh) 2005-02-09
JP5031140B2 (ja) 2012-09-19
CN1279691A (zh) 2001-01-10
CA2308604A1 (en) 1999-05-20
WO1999024473A1 (en) 1999-05-20
KR100513418B1 (ko) 2005-09-09
TR200001265T2 (tr) 2000-09-21
JP2001522865A (ja) 2001-11-20
EP1042368A1 (de) 2000-10-11
US20040063914A1 (en) 2004-04-01
AU1871299A (en) 1999-05-31
RU2218178C2 (ru) 2003-12-10
PL195985B1 (pl) 2007-11-30
HUP0004099A3 (en) 2002-01-28
CZ20001684A3 (cs) 2000-11-15
BR9813988A (pt) 2000-09-26
CA2308604C (en) 2009-12-15
HUP0004099A1 (en) 2001-03-28
US6649421B1 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
BR9106394A (pt) Anticorpos anti-icam-1 quimericos humanizados,processos de preparacao e uso
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
DE69520149T2 (de) Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE69306803T2 (de) Kleinzelliger lungenkarzinom-spezifischer antikörper und antigenen
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ES2121358T3 (es) Anticuerpos monoclonales humanizados contra interleuquina-4 humana.
EP0816496A3 (de) Nierenkarzinom-spezifische-T-Zellen
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
EP1388543A3 (de) Antikörper gegen VASP (Vasodilator-stimulated phosphoprotein), Hybridomzellen für deren Gewinnung und deren Verwendung
ATE335504T1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
BR9815776A (pt) Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis
BR9815775A (pt) Anticorpos monoclonais anti-antìgeno carcinoembriÈnico (cea) humanizados de elevada afinidade
ES2088820B1 (es) Anticuerpos monoclonales antineumolisina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1042368

Country of ref document: EP

REN Ceased due to non-payment of the annual fee